ERS 2026: oral IRAK4 inhibitor AZD6793 enters dose-ranging Phase IIb COPD trial
The primary endpoint is the annualised rate of moderate or severe COPD exacerbations over 24 weeks.
The primary endpoint is the annualised rate of moderate or severe COPD exacerbations over 24 weeks.